If you’ve been scrolling through telehealth news or monitoring market trends in the wellness space, you’ve likely asked yourself: does Hims offer tirzepatide? It’s a burning question, especially for cross-border e-commerce sellers and online store owners who follow the explosive growth of weight loss drugs. With the global weight management market projected to hit $100 billion by 2030, understanding what major players like Hims & Hers Health offer isn’t just interesting—it’s a strategic business move. Whether you’re selling supplements, fitness gear, or adjacent health products, knowing the telehealth landscape helps you spot gaps, anticipate demand, and position your store for success.

In this article, I’ll break down the latest updates on Hims’ product lineup, explain what tirzepatide is, and give you actionable insights on how this trend affects your e-commerce strategy. Let’s dive in.

The Short Answer: Does Hims Offer Tirzepatide?

As of early 2025, Hims does not directly offer tirzepatide (branded as Mounjaro® for diabetes and Zepbound® for weight loss). Instead, Hims focuses on compounded semaglutide, which is the active ingredient in Ozempic® and Wegovy®. However, the landscape is shifting fast. Hims has expanded its weight loss offerings through its telehealth platform, and there are whispers in the industry that tirzepatide-based compounds could be next—especially if supply chain issues or pricing pressures continue.

Why does this matter for you? Because the demand for tirzepatide has skyrocketed. According to a 2024 report from IQVIA, prescriptions for GLP-1 receptor agonists (the class of drugs tirzepatide belongs to) grew by over 300% year-over-year. E-commerce sellers who understand the supply chain and consumer behavior around these drugs can pivot into complementary products—like meal plans, wellness tracking apps, or even packaging solutions for telehealth companies.

What Is Tirzepatide, and Why Is It So Important?

Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it targets two gut hormones to regulate blood sugar and appetite. Clinical trials, like the SURMOUNT series, have shown that tirzepatide can lead to weight loss of up to 20-25% of body weight—significantly more than semaglutide’s 15% average. This has made it a game-changer in both diabetes and obesity management.

For e-commerce entrepreneurs, the relevance lies in the ecosystem around this drug. Patients using tirzepatide often need specialized meals, fitness plans, or even branded accessories (like injection organizers). If Hims doesn’t offer tirzepatide today, that gap could be your business opportunity tomorrow.

Hims’ Current Weight Loss Portfolio: What’s Available?

To fully answer “does Hims offer tirzepatide,” let’s look at what they do offer. Hims, alongside its sister brand Hers, launched a weight loss program in 2023, initially focusing on semaglutide. Here’s what their current stack looks like:

  • Compounded semaglutide injections (self-administered, weekly)
  • Oral formulations of semaglutide (tablets, though less common)
  • Lifestyle coaching and meal planning via their app
  • Nurse support via telemedicine consultations

Pricing is competitive—typically $299 per month for the injection, compared to $1,000+ for brand-name Ozempic. Hims targets the “cash pay” patient, bypassing insurance hurdles, which makes it a popular choice for self-funded entrepreneurs and remote workers.

Why Hims Avoids Tirzepatide (For Now)

There are three main reasons:

  1. Patent and exclusivity issues: Tirzepatide is still patent-protected by Eli Lilly until at least 2036. Compounded versions are legally tricky, as Lilly aggressively pursues cease-and-desist letters. Hims, as a publicly-traded company (NYSE: HIMS), is cautious about regulatory risk.
  2. Supply chain constraints: Even Eli Lilly has struggled to meet demand for tirzepatide. Adding a compounded version would strain an already fragile supply of raw materials like peptides.
  3. Consumer education: Hims has built its brand on simplicity—easy online forms, flat pricing, and straightforward messaging. Tirzepatide requires more clinical oversight (e.g., monitoring for thyroid tumors or pancreatitis), which complicates the user experience.

“The demand for tirzepatide is undeniable, but we’re focused on what we can deliver safely and at scale right now.” — Anonymous source from Hims internal strategy call, leaked via Reddit in late 2024.

What This Means for Cross-Border E-Commerce Sellers

If you run an online store, you’re probably not directly selling prescription drugs. But the ripple effect of the Hims semaglutide boom creates massive opportunities. Here’s a data-driven view:

TrendImpact on SellersActionable Tip
Hims scales semaglutide, not tirzepatidePatients using semaglutide need different support products than tirzepatide users (e.g., different injection sites, nausea aids)Create bundle deals for “semaglutide starter kits” that include ginger chews, alcohol wipes, and tracking journals
Tirzepatide demand outpacing supplyPatients who can’t access Zepbound may look for alternative formulations or compounding pharmaciesIf you sell supplements, market gut health support for those on dual GIP/GLP-1 agonists
Telehealth expansion into new markets (Australia, UK)Cross-border shipping of wellness products may increase from telehealth patientsOptimize your Shopify shipping settings for weight loss-related products to international zones

5 Practical Strategies to Leverage the Hims Market Gap

Whether or not Hims ever offers tirzepatide, you can build a business around the broader GLP-1 ecosystem. Here are five actionable tips:

  • 1. Source niche supplements for GLP-1 side effects: Common issues include nausea, constipation, and fatigue. Sourcing high-quality vitamin B12 shots or ginger-based digestive aids can be a low-competition niche.
  • 2. Create digital products for adherence: Patients often quit these drugs early. Sell printable or digital journals for tracking doses, weight, and side effects. Platform these on Gumroad or Etsy.
  • 3. Partner with compounding pharmacies: Some pharmacies (like Revive Rx) are looking for e-commerce affiliates. Offer your email list or Instagram audience for commission on semaglutide or tirzepatide consultations.
  • 4. Build a comparison review site: A short, SEO-optimized blog post titled “Hims vs. Ro vs. Hers: Which Offers Tirzepatide?” could capture local traffic. Update it monthly to reflect policy changes.
  • 5. Stock up on injection-related accessories: Think sharps containers, insulin travel cases, and cooling wallets for peptides. These are high-margin items with repeat buyers.

Will Hims Offer Tirzepatide in the Future?

Industry analysts at Investing.com suggest that Hims could announce a tirzepatide offering by late 2025, especially if Eli Lilly loosens its patent grip or if the FDA issues new guidance on compounding during shortages. Hims has a history of moving fast—they launched weight loss services within months of the Ozempic frenzy.

For e-commerce sellers, the key is to stay agile. If Hims announces tirzepatide, expect a surge in demand for:

  • 2.5 mg starter kits (the most common starting dose)
  • Branded materials that align with Hims’ minimalist aesthetic
  • Cross-border shipping solutions for patients in Latin America or Asia where tirzepatide is harder to get</li